Abstract

This study addresses the efficacy and safety of interferon alpha-2b compared to interferon alpha-2b and ribavirin in hepatitis C patients who had previously responded to interferon but relapsed after therapy was stopped. The biochemical and virological response to treatment are measured at two time points: at the end of treatment and six months posttreatment sustained response. Secondary endpoints include improvement in liver biopsy at posttreatment, time to response and time to relapse. Based on these markers, this randomized clinical trial preliminary data suggests the treatment with combined therapy brings improvement in sustained responses of 50-60% compared to 26-30% of interferon alpha 2b alone. Future studies will focus on the need to provide optimal treatment during the initial course of therapy based on the finding that retreatment of initial responders who relapse is associated with a lower end of treatment response than previously reported.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Center for Research Resources (NCRR)
Type
General Clinical Research Centers Program (M01)
Project #
3M01RR000833-24
Application #
6279313
Study Section
Project Start
1997-12-01
Project End
1998-11-30
Budget Start
1997-10-01
Budget End
1998-09-30
Support Year
24
Fiscal Year
1998
Total Cost
Indirect Cost

  Institution

Name
Scripps Research Institute
Department
Type
DUNS #
City
La Jolla
State
CA
Country
United States
Zip Code
92037

  Publications

Winn, Virginia D; Gormley, Matthew; Fisher, Susan J (2011) The Impact of Preeclampsia on Gene Expression at the Maternal-Fetal Interface. Pregnancy Hypertens 1:100-8
Delaney, Joseph A C; Scherzer, Rebecca; Biggs, Mary L et al. (2010) Associations of antiretroviral drug use and HIV-specific risk factors with carotid intima-media thickness. AIDS 24:2201-9
Pan, Warren W; Li, Jain-Dong; Huang, Shuang et al. (2010) Synergistic activation of NF-{kappa}B by bacterial chemoattractant and TNF{alpha} is mediated by p38 MAPK-dependent RelA acetylation. J Biol Chem 285:34348-54
Huang, XueSong; Chen, Ling-Yu; Doerner, Astrid M et al. (2009) An atypical protein kinase C (PKC zeta) plays a critical role in lipopolysaccharide-activated NF-kappa B in human peripheral blood monocytes and macrophages. J Immunol 182:5810-5
Mukherjee, Sumanta; Chen, Ling-Yu; Papadimos, Thomas J et al. (2009) Lipopolysaccharide-driven Th2 cytokine production in macrophages is regulated by both MyD88 and TRAM. J Biol Chem 284:29391-8
Chen, Ling-Yu; Pan, Zhixing K (2009) Synergistic activation of leukocytes by bacterial chemoattractants: potential drug targets. Endocr Metab Immune Disord Drug Targets 9:361-70
Chen, Ling-Yu; Pan, Warren W; Chen, Miao et al. (2009) Synergistic induction of inflammation by bacterial products lipopolysaccharide and fMLP: an important microbial pathogenic mechanism. J Immunol 182:2518-24
Ito, Tatsuo; Yadav, Neelu; Lee, Jaeho et al. (2009) Arginine methyltransferase CARM1/PRMT4 regulates endochondral ossification. BMC Dev Biol 9:47
Price, Richard W; Parham, Robin; Kroll, Jing Lu et al. (2008) Enfuvirtide cerebrospinal fluid (CSF) pharmacokinetics and potential use in defining CSF HIV-1 origin. Antivir Ther 13:369-74
Dawson, Arthur; Abel, Susan L; Loving, Richard T et al. (2008) CPAP therapy of obstructive sleep apnea in type 2 diabetics improves glycemic control during sleep. J Clin Sleep Med 4:538-42

Showing the most recent 10 out of 871 publications